Performance and Safety of Mepilex® Up in Leg and Foot Ulcers and Skin Tears

This prospective, open-label, multicenter, post-market clinical follow-up investigation will evaluate Mepilex® Up used as the primary absorbent dressing in the treatment of exuding ulcers and skin tears located on the leg and foot. Approximately 70 adult participants will be enrolled and followed for up to 6 weeks or until wound healing, whichever occurs first. Assessments include wound progression, wound healing, wound area reduction, peri-wound skin condition, dressing performance, participant-reported pain, and safety outcomes. Treatment and wound care procedures will follow local standard clinical practice.

Inclusion criteria

• Signed informed consent.
• Adults aged ≥18 years
• Exudate levels moderate to high
• Wound sizes:

• Leg ulcers: between 3 cm² and 30 cm²
• Foot ulcers: ≥0,75 cm²
• Skin tears: between 3 cm² and 30 cm²
• Pressure ulcers: Foot ulcer caused by pressure

Exclusion criteria

• Circumferential ulcer
• Known allergy/hypersensitivity to the materials of the dressings or products
• Use of wound fillers
• Infected ulcer/wound, defined as any wound condition requiring the prescription or continuation of systemic antibiotics (orally or parental) at enrolment
• Participating in ongoing clinical investigations, or during the past 30 days, which may impact the outcome of this investigation based on the judgement of the investigator
• Woman of childbearing potential, who is pregnant or breastfeeding or plans on becoming pregnant during the investigation period
• Not willing or able to comply to clinical investigation procedures, or not suitable for participation according to the investigator (e.g., alcohol or substance abuse)